A Benchmarking System to Spark Companies to Action - Innovation That Fuels New Deal Flow and Growth Pipelines
12-Jan-2026
Global
Frost Radar
DB61-01-00-00-00
HC_2026_34264
Artificial intelligence (AI) has been revolutionizing the technology-enabled drug discovery and development landscape. In clinical research, AI has been gaining traction across site selection, trial design and protocol optimization, and patient recruitment and management. Because data is the core discipline of drug development, electronic medical records and real-world evidence also support trial outcomes and improve drug efficiency. AI can create structured databases from disparate and unstructured sources, simplifying data assessment and enhancing trial safety and efficiency. Sophisticated generative and agentic AI-based technologies and real-world data and copilot-based large language models provide real-time database access to target the right patient to the right clinical trial. AI-driven solutions used in clinical trial design, site selection, and patient identification and retention can reduce costs, increase efficiency, and support the transition to decentralized trials by means of remote patient recruitment, management, and engagement. Interactive platforms ensure better patient adherence and greater retention. For this Frost Radar analysis, Frost & Sullivan selected companies that reflect a sharp focus on innovative AI technologies for clinical trial support and real-world evidence generation and access and a goal to overcome the key challenges across the highly mature clinical trials industry.
Frost & Sullivan analyzes numerous companies in an industry. Those selected for further analysis based on their leadership or other distinctions are benchmarked across 10 Growth and Innovation criteria to reveal their position on the Frost Radar. The publication presents competitive profiles of each company on the Frost Radar considering their strengths and the opportunities that best fit those strengths.
AiCure
AWS
BostonGene
ConcertAI
Deep 6 AI
Oncshot
Paradigm Health
Phesi, Inc.
QuantHealth
Saama Technologies
Unlearn
Significance of Being on the Frost Radar
CEO’s Growth Team
Investors
Customers
Board of Directors
Frost Radar™: Benchmarking Future Growth Potential 2 Major Indices, 10 Analytical Ingredients, 1 Platform
Growth Index
Growth Index (GI) is a measure of a company’s growth performance and track record, along with its ability to develop and execute a fully aligned growth strategy and vision; a robust growth pipeline system; and effective market, competitor, and end-user focused sales and marketing strategies.
-
Market Share (previous 3 years)
This is a comparison of a company’s market share relative to its competitors in a given market space for the previous 3 years. -
Revenue Growth (previous 3 years)
This is a look at a company’s revenue growth rate for the previous 3 years in the market/industry/category that forms the context for the given Frost Radar™. -
Growth Pipeline
This is an evaluation of the strength and leverage of a company’s growth pipeline system to continuously capture, analyze, and prioritize its universe of growth opportunities. -
Vision and Strategy
This is an assessment of how well a company’s growth strategy is aligned with its vision. Are the investments that a company is making in new products and markets consistent with the stated vision? -
Sales and Marketing
This is a measure of the effectiveness of a company’s sales and marketing efforts in helping it drive demand and achieve its growth objectives.
Innovation Index
Innovation Index (II) is a measure of a company’s ability to develop products/ services/ solutions (with a clear understanding of disruptive Mega Trends) that are globally applicable, are able to evolve and expand to serve multiple markets and are aligned to customers’ changing needs.
-
INNOVATION SCALABILITY
This determines whether an organization’s innovations are globally scalable and applicable in both developing and mature markets, and also in adjacent and non-adjacent industry verticals. -
RESEARCH AND DEVELOPMENT
This is a measure of the efficacy of a company’s R&D strategy, as determined by the size of its R&D investment and how it feeds the innovation pipeline. -
PRODUCT PORTFOLIO
This is a measure of a company’s product portfolio, focusing on the relative contribution of new products to its annual revenue. -
MEGATRENDS LEVERAGE
This is an assessment of a company’s proactive leverage of evolving, long-term opportunities and new business models, as the foundation of its innovation pipeline. -
CUSTOMER ALIGNMENT
This evaluates the applicability of a company’s products/services/solutions to current and potential customers, as well as how its innovation strategy is influenced by evolving customer needs.
Significance of Being on the Frost Radar™
Companies plotted on the Frost RadarTM are the leaders in the industry for growth, innovation, or both. They are instrumental in advancing the industry into the future.
-
GROWTH POTENTIAL
Your organization has significant future growth potential, which makes it a Company to Action. -
BEST PRACTICES
Your organization is well positioned to shape Growth Pipeline™ best practices in your industry. -
COMPETITIVE INTENSITY
Your organization is one of the key drivers of competitive intensity in the growth environment. -
CUSTOMER VALUE
Your organization has demonstrated the ability to significantly enhance its customer value proposition. -
PARTNER POTENTIAL
Your organization is top of mind for customers, investors, value chain partners, and future talent as a significant value provider.
Speak directly with our analytics experts for tailored recommendations.
Recent related Healthcare research
25 Sep 2026 | Global | Technology Research
Innovations and Growth Opportunities in Advanced Medical Devices, Diagnostic Solutions, and Implantables
The latest issue of Advanced MedTech Technology Opportunity Engine (TOE) spotlights a diverse slate of innovations across advanced medical devices, diagnostic solutions, and implantables.The issue features advanced medical devices such as peritoneal dialysis fluid system, cold sterilization-based au...
23 Sep 2026 | Global | Technology Research
Programmable Epigenome Editing for Disease Reversal
Programmable epigenome editing is developing as a distinct approach to controlling gene activity without changing the underlying DNA sequence. This report examines the landscape from the core editing technologies and delivery systems through the companies, academic programs and therapeutic applicati...
21 Sep 2026 | Europe | Market Research
HLTH Europe 2026: Five Key Takeaways and Growth Opportunities
HLTH Europe 2026, held in Amsterdam, brought together more than 5,000 stakeholders spanning providers, payers, health systems, technology vendors, start-ups, investors, and policymakers, providing a comprehensive view of the evolving European digital health landscape. Across conference sessions and ...
21 Sep 2026 | Global | Frost Radar
Frost Radar: Smart Nutraceuticals for Brain Health, 2026
This Frost Radar evaluates the evolving smart nutraceuticals landscape as consumer awareness of cognitive health, lifestyle-related stress, and healthy aging creates demand for scientifically validated, natural, and multifunctional brain health solutions. The market remains fragmented, with differen...
18 Sep 2026 | Global | Frost Radar
Frost Radar™: Life Sciences Laboratory Information Management Systems, 2026
Laboratory information management systems (LIMS) have been used in life sciences since laboratories began digitizing sample tracking and data management in the 1970s. Modern LIMS solutions enhance efficiency by automating workflows, improving data accuracy, and enabling seamless integration and offe...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
Frost & Sullivan analyzes numerous companies in an industry. Those selected for further analysis based on their leadership or other distinctions are benchmarked across 10 Growth and Innovation criteria to reveal their position on the Frost Radar. The publication presents competitive profiles of each company on the Frost Radar considering their strengths and the opportunities that best fit those strengths.
| Deliverable Type | Frost Radar |
|---|---|
| Industries | Healthcare |
| No Index | No |
| Is Prebook | No |
| Keyword 1 | ai clinical trials market |
| Keyword 2 | digital clinical trial platforms |
| Keyword 3 | pharma ai analytics |
| Podcast | No |
| Predecessor | PFKD-01-00-00-00 |
| WIP Number | DB61-01-00-00-00 |